Mikacin Injection
✅ Treats bacterial infections
✅ Intramuscular or intravenous use
✅ Effective against resistant bacteria
✅ Reduces infection symptoms
✅ Promotes faster recovery
✓ Medicinsk gennemgået af Morgan Ellis — Apoteksforsker · 8 års erfaring · Sidst gennemgået: maj 2026
⚡ Quick Answer — What is Mikacin Injection?
Mikacin Injection is an amikacin IV / IM injection (Aristo) — an aminoglycoside antibiotic for severe Gram-negative sepsis, Pseudomonas pneumonia, and complicated UTI. Hospital use only with mandatory therapeutic drug monitoring. Black-box: nephrotoxicity, ototoxicity, neuromuscular blockade.
📦 Hver ordre er dækket af vores Reshipment Assurance Policy — hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.
Hvorfor bestille fra MedsBase
Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomspændende i diskret, neutral emballage — ingen medicinnavn på pakkens ydre. Kortbetalinger håndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor — aldrig “MedsBase” eller medicinnavn). Crypto og SEPA bankoverførsel accepteres også. Hver ordre er dækket af vores Reshipment Assurance Policy.
How Mikacin Injection works
Mikacin Injection contains amikacin, an aminoglycoside antibiotic that binds the 30S ribosomal subunit, induces misreading of mRNA codons, and inhibits bacterial protein synthesis. It is bactericidal with concentration-dependent killing and a long post-antibiotic effect — supporting once-daily extended-interval dosing for most indications. Spectrum: aerobic Gram-negative rods (Pseudomonas aeruginosa, Klebsiella, Enterobacter, Serratia, Acinetobacter, Proteus, Citrobacter), and synergy with cell-wall agents against Enterococcus and viridans streptococci. Activity against atypical mycobacteria (M. tuberculosis MDR strains, M. abscessus). No activity against anaerobes or most Gram-positives as monotherapy.
Indications & dosing
| Indikation | Dosis | Varighed |
|---|---|---|
| Severe Gram-negative sepsis (pyelonephritis, intra-abdominal — combination) | 15 mg/kg once daily (extended-interval) OR 7.5 mg/kg every 12 h | 5–7 days then de-escalate |
| Pseudomonas pneumonia (combination with cefepime / piperacillin-tazobactam / meropenem) | 15 mg/kg once daily | 5–14 days |
| Complicated UTI / catheter-associated | 15 mg/kg once daily | 5–7 days |
| Endocarditis (combination, gentamicin alternative) | 7.5 mg/kg every 12 h | 4–6 weeks |
| MDR-TB regimen (specialist use) | 15 mg/kg once daily | Per regimen |
| MAC / M. abscessus (combination) | 15 mg/kg three times weekly | Refer specialist |
Dose adjustment: use ideal body weight (or adjusted weight if obese). Reduce dose / extend interval in renal impairment based on creatinine clearance. Therapeutic drug monitoring is mandatory — target peak 50–60 mg/L (extended-interval) and trough < 1 mg/L for most indications.
Aminoglycosides cause dose- and duration-related nephrotoxicity (15–25% of treated patients) and ototoxicity — both vestibular (balance / vertigo) and cochlear (high-frequency hearing loss). Hearing loss can be permanent; vestibular damage often is too. Risk factors: advanced age, baseline renal impairment, dehydration, concurrent loop diuretics / vancomycin / cisplatin / amphotericin / NSAIDs / contrast, prolonged courses (> 7 days). Aminoglycosides also potentiate neuromuscular blockade — caution in myasthenia gravis and during anaesthesia. Mitochondrial DNA m.1555A>G mutation predicts severe rapid-onset hearing loss after even a single dose; genetic screening is increasingly recommended where rapid testing exists.
Bivirkninger
- Nephrotoxicity: non-oliguric acute tubular necrosis, usually reversible if caught early and the drug stopped.
- Ototoxicity: high-frequency hearing loss (cochlear) and / or balance disturbance (vestibular). Often irreversible. Test pre- and during prolonged courses.
- Neuromuscular blockade: weakness, respiratory depression — particularly with myasthenia and during anaesthesia.
- Local injection-site reactions; phlebitis at IV sites.
- Allergic skin reactions.
Kontraindikationer
- Known aminoglycoside hypersensitivity.
- Severe pre-existing renal or auditory impairment.
- Myasthenia gravis (relative — neuromuscular blockade).
- Pregnancy (especially first and second trimester) — relative; risk of fetal ototoxicity.
- Concurrent loop diuretics in elderly with renal impairment (additive nephro/oto-toxicity).
Lægemiddelinteraktioner
| Lægemiddel | Effekt | Action |
|---|---|---|
| Loop diuretics (furosemide / bumetanide) | Additive ototoxicity | Avoid combination if possible |
| Vancomycin / cisplatin / amphotericin / IV contrast / NSAIDs | Additive nephrotoxicity | Monitor renal function daily |
| Neuromuscular blockers (vecuronium, rocuronium) | Prolonged paralysis | Communicate with anaesthesia team |
| Cephalosporins (high dose) | Possible additive nephrotoxicity | Monitor closely |
| Bisphosphonates / penicillins / other beta-lactams (in same syringe) | Aminoglycoside is inactivated by beta-lactams in vitro | Administer in separate lines / stagger |
Pregnancy & Breastfeeding
Aminoglycosides are category D — fetal ototoxicity reported. Avoid in pregnancy unless treating life-threatening infection without alternatives.
Opbevaring
Store below 25 °C, away from direct sunlight and moisture. Keep in original packaging. Keep out of reach of children. Discard any unused tablets after the printed expiry date — degraded antibiotics can lose potency or release breakdown products.
This medicine is only effective against bacterial infections. Do not use it for viral illnesses (common cold, most sore throats, flu, COVID-19), do not stop early when you feel better, and do not save leftovers for future infections. Misuse drives drug-resistant bacteria like MRSA, ESBL, and CRE — the WHO ranks antimicrobial resistance among the top 10 global public-health threats.
Ofte stillede spørgsmål
How is Mikacin Injection given?
Mikacin Injection is administered in hospital by intramuscular injection or intravenous infusion. Dosing is weight- and renal-function-based, with peak / trough therapeutic drug monitoring to balance efficacy and toxicity.
How long does treatment usually last?
Most empirical aminoglycoside therapy is 3–7 days as part of combination treatment, then de-escalated based on culture and clinical response. Endocarditis and MDR-TB require much longer specialist regimens.
Why is hearing loss a concern?
Aminoglycosides accumulate in inner-ear hair cells. Permanent high-frequency cochlear damage and vestibular dysfunction are dose- and duration-related. Audiometry is recommended pre- and during prolonged courses.
What about my kidneys?
Acute tubular necrosis is the most common toxicity (15–25% of courses). It is usually reversible if the drug is stopped promptly — daily creatinine, urine output, and trough-level monitoring catch it early.
Can it interact with my pre-existing weakness?
Yes — aminoglycosides potentiate neuromuscular blockade. In myasthenia gravis the muscle weakness can worsen sharply. Tell every clinician about a myasthenia diagnosis before any procedure.
What is once-daily dosing?
Modern regimens give the entire daily dose as a single infusion (extended-interval dosing). This exploits the long post-antibiotic effect and reduces nephrotoxicity by allowing the drug to clear between doses. Trough levels guide subsequent dose timing.
Can I have it during pregnancy?
Aminoglycosides are typically avoided in pregnancy because of fetal ototoxicity. Use only when treating life-threatening infections without alternatives.
What does “synergy with penicillin” mean?
For some serious infections (enterococcal endocarditis, listeria meningitis), pairing an aminoglycoside with a cell-wall agent gives faster bactericidal activity than either drug alone. The aminoglycoside dose is lower than for Gram-negative sepsis.
Is there a safer alternative for my Pseudomonas infection?
Cefepime, piperacillin-tazobactam, meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam are alternatives. Aminoglycosides are usually used in combination rather than as monotherapy because of resistance and toxicity.
What should I tell future doctors about this drug?
Note any baseline / post-treatment audiometry results, peak creatinine, and the cumulative dose. If you carry a mitochondrial m.1555A>G mutation, document it — future aminoglycoside exposure should be avoided.
Aminoglycosides like Mikacin Injection (amikacin) handle Gram-negative bacteraemia but carry renal and ototoxic risk on prolonged use, so once cultures stabilise, clinicians frequently step down to a less nephrotoxic fluoroquinolone such as Lynx Injection (levofloxacin 2 ml IV) for the remainder of the course.
Other Antibiotics & Anti-Infective Medications
- Levomac (Levofloxacin) — respiratory fluoroquinolone
- Cifran (Ciprofloxacin) — UTI / GI / Pseudomonas cover
- Moxif (Moxifloxacin) — broad respiratory cover with anaerobic activity
- Azee (Azithromycin) — atypical-pathogen alternative
- Augmentin (Amoxicillin + Clavulanic acid) — beta-lactam alternative
More options in Antibiotics
Rangeret efter seneste MedsBase ordrevolumen — hvad andre kunder i denne kategori vælger.
| Styrke | 100 mg, 250 mg, 500 mg |
|---|---|
| Antal | 1 Injection/s, 3 Injection/s, 6 Injection/s |
| Pharma Form | Injection/s |
| Manufacturer | Aristo Pharma |
| Treatment | Bacterial infections |
| Generic Brand | Amikacin |
Mikacin Injection
Spørgsmål & svar
Mikacin Injection
Relaterede produkter
Anmeldelser
Der er ingen anmeldelser endnu